Biopolymers and cell. 2003; 19 (3): 262 - 269

Usage of new bacterial adjuvants for vaccination by anti-influenza and anti-poliomyelitis vaccines

S. L. Rybalko, M. L. Khristova, A. V. Shapiro, L. D. Varbanets, N. L. Zubkova, V. I. Zadorozhna, N. V. Ivans'ka, I. B. Sorokulova, T. F. Grytsak, T. M. Furzikova, I. I. Pinchuk, Yu. V. Patskovski, S. T. Diadiun, V. V. Smirnov, M. A. Urdaci

The authors have compared activities of three bacterial adjuvant-neuraminins isolated from culture fluids of Staphylococcus aureus, Streptococcus pneumoniae and Bacillus subtilis 105 taking into consideration their influence on the immune response following anti-influenza and anti-poliomyelitis vaccination. Bacterial adjuvants stimulate humoral immune response and help to develop more early anti-influenza IgG together with IgM antibodies (on the first week of immunization). This phenomenon may be due to the peptide mimicry of neuraminins and influenza virus hemagglutinins. In an animal model the S. aureus neuraminin is shown to stimulate a more prolonged antibody synthesis against polioviruses types 1 and 3. Due to such mimicry, neuraminins may be used for priming and acceleration of prolonged immune answer following booster immunization. Being non-toxic, neuraminins are promising compounds for the adjuvant therapy.